



Labcorp Completes Acquisition of Select Assets of Crouse Health’s Laboratory Alliance of Central New York’s Laboratory Business; Enters Agreement to Manage Crouse’s Inpatient Laboratory

March 19, 2026

BURLINGTON, N.C., March 19, 2026 - Labcorp, a global leader of innovative and comprehensive laboratory services, announced today that it has completed its acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York’s (Lab Alliance) laboratory business. Labcorp also has entered into a strategic agreement with Crouse Health to manage daily operations of its inpatient laboratory.

As part of the transaction, Labcorp will assume operation of Lab Alliance’s 12 patient service centers (PSCs). The transaction is expected to strengthen access to high-quality, affordable diagnostic services for patients and providers across Central New York through Labcorp’s expanded test menu, robust data and digital tools like Diagnostic Assistant and Test Finder.

“Labcorp is proud to bring greater access and choice for laboratory services to the communities of Greater Central New York,” said Bill Haas, Senior Vice President, Labcorp’s Northeast Division. “Lab Alliance has built an outstanding reputation for laboratory services, and our goal is to build on that foundation by bringing expanded testing capabilities, scientific expertise and national-scale resources to the patients and providers who depend on timely, high-quality diagnostics. We are also very excited to be an integrated inpatient partner with Crouse Health for years to come.”

This acquisition follows other strategic relationships that Labcorp has developed with a range of health systems and regional/local laboratories that have increased access to laboratory services, improved patient care and driven efficiencies for customers.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits of Labcorp’s acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York’s (Lab Alliance) laboratory business and agreement to manage daily operations of the Crouse Health inpatient laboratory.

Media

Neil Hirsch

Media@Labcorp.com

Investors

Dewey Steadman

Investor@Labcorp.com